BioVersys AG (XSWX:BIOV) LT-Debt-to-Total-Asset: 0.24 (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG LT-Debt-to-Total-Asset?

BioVersys AG XSWX:BIOV 4 LT-Debt-to-Total-Asset is 0.24 as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioVersys AG's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.24.

BioVersys AG's long-term debt to total assets ratio declined from Dec. 2024 (0.39) to Dec. 2025 (0.24). It may suggest that BioVersys AG is progressively becoming less dependent on debt to grow their business.

BioVersys AG  (XSWX:BIOV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioVersys AG LT-Debt-to-Total-Asset Related Terms

BioVersys AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioVersys AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG LT-Debt-to-Total-Asset Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
LT-Debt-to-Total-Asset
0.39 0.24

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset 0.00 0.39 0.15 0.24
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG LT-Debt-to-Total-Asset Calculation

BioVersys AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=21.44/90.636
=0.24

BioVersys AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=21.44/90.636
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.24 mean?
BioVersys AG (XSWX:BIOV) has a LT-Debt-to-Total-Asset of 0.24 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's LT-Debt-to-Total-Asset too high?
BioVersys AG's current LT-Debt-to-Total-Asset is 0.24. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's LT-Debt-to-Total-Asset compare to VRTX and REGN?
BioVersys AG's LT-Debt-to-Total-Asset of 0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioVersys AG and its competitors. BioVersys AG's current LT-Debt-to-Total-Asset is 0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current LT-Debt-to-Total-Asset of 0.24. The current LT-Debt-to-Total-Asset is 0.24. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current LT-Debt-to-Total-Asset is 0.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price